Moderna, Inc. (MRNA) stock
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30511% above fair value
$195.00−4.33 (-2.17%)
Close on Nov 20, 2026Market cap $77.85BP/E –Yield –
Moderna free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Moderna's free cash flow for the twelve months ending Jun 30, 2026 was -$1.24B. For fiscal 2025 it was -$2.07B. The highest annual figure on record is $13.34B in fiscal 2021.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$2.07B | – |
| FY2024 | Dec 31, 2024 | -$4.06B | – |
| FY2023 | Dec 31, 2023 | -$3.83B | -183.5% |
| FY2022 | Dec 31, 2022 | $4.58B | -65.6% |
| FY2021 | Dec 31, 2021 | $13.34B | +580.8% |
| FY2020 | Dec 31, 2020 | $1.96B | – |
| FY2019 | Dec 31, 2019 | -$491.00M | – |
| FY2018 | Dec 31, 2018 | -$436.63M | – |
| FY2017 | Dec 31, 2017 | -$389.89M | -1260.7% |
| FY2016 | Dec 31, 2016 | $33.59M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$563.00M | – |
| Q1 FY2026 | Mar 31, 2026 | -$692.00M | – |
| Q4 FY2025 | Dec 31, 2025 | $891.00M | +194.1% |
| Q3 FY2025 | Sep 30, 2025 | -$880.00M | – |
| Q2 FY2025 | Jun 30, 2025 | -$922.00M | – |
| Q1 FY2025 | Mar 31, 2025 | -$1.15B | – |
| Q4 FY2024 | Dec 31, 2024 | $303.00M | -24.6% |
| Q3 FY2024 | Sep 30, 2024 | -$1.72B | – |
| Q2 FY2024 | Jun 30, 2024 | -$1.46B | – |
| Q1 FY2024 | Mar 31, 2024 | -$1.19B | – |
| Q4 FY2023 | Dec 31, 2023 | $402.00M | -74.4% |
| Q3 FY2023 | Sep 30, 2023 | -$1.74B | -1167.5% |
| Q2 FY2023 | Jun 30, 2023 | -$1.15B | -629.5% |
| Q1 FY2023 | Mar 31, 2023 | -$1.34B | -150.9% |
| Q4 FY2022 | Dec 31, 2022 | $1.57B | -50.8% |
| Q3 FY2022 | Sep 30, 2022 | $163.00M | -94.9% |
| Q2 FY2022 | Jun 30, 2022 | $217.00M | -94.6% |
| Q1 FY2022 | Mar 31, 2022 | $2.63B | -10.4% |
| Q4 FY2021 | Dec 31, 2021 | $3.19B | +157.3% |
| Q3 FY2021 | Sep 30, 2021 | $3.18B | +263.5% |
| Q2 FY2021 | Jun 30, 2021 | $4.03B | – |
| Q1 FY2021 | Mar 31, 2021 | $2.94B | – |
| Q4 FY2020 | Dec 31, 2020 | $1.24B | – |
| Q3 FY2020 | Sep 30, 2020 | $874.00M | – |
| Q2 FY2020 | Jun 30, 2020 | -$43.00M | – |
| Q1 FY2020 | Mar 31, 2020 | -$112.00M | – |
| Q4 FY2019 | Dec 31, 2019 | -$106.16M | – |
| Q3 FY2019 | Sep 30, 2019 | -$113.80M | – |
| Q2 FY2019 | Jun 30, 2019 | -$119.17M | – |
| Q1 FY2019 | Mar 31, 2019 | -$151.86M | – |
| Q4 FY2018 | Dec 31, 2018 | -$104.66M | – |
| Q3 FY2018 | Sep 30, 2018 | -$106.35M | – |
| Q2 FY2018 | Jun 30, 2018 | -$82.33M | – |
| Q1 FY2018 | Mar 31, 2018 | -$143.29M | – |
See a number that looks wrong?